The presentation of data by Ignite Proteomics, a subsidiary of IMAC Holdings, at a major conference could enhance the company's reputation in cancer research. The finding that MHC-II is a superior predictor of pembrolizumab response may attract attention from the medical community and investors, potentially boosting the stock price.